BRPI0520451A2 - métodos para tratamento de distúrbios associados a substáncias quìmicas - Google Patents
métodos para tratamento de distúrbios associados a substáncias quìmicasInfo
- Publication number
- BRPI0520451A2 BRPI0520451A2 BRPI0520451-8A BRPI0520451A BRPI0520451A2 BR PI0520451 A2 BRPI0520451 A2 BR PI0520451A2 BR PI0520451 A BRPI0520451 A BR PI0520451A BR PI0520451 A2 BRPI0520451 A2 BR PI0520451A2
- Authority
- BR
- Brazil
- Prior art keywords
- sub
- phenyl
- alkyl
- group
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000126 substance Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2005/026439 WO2007018496A1 (en) | 2005-07-26 | 2005-07-26 | Methods for treating substance-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0520451A2 true BRPI0520451A2 (pt) | 2009-05-12 |
Family
ID=35064669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0520451-8A BRPI0520451A2 (pt) | 2005-07-26 | 2005-07-26 | métodos para tratamento de distúrbios associados a substáncias quìmicas |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1928451B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5094720B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101199499B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101272776B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE538784T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005335241B9 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0520451A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2616721C (cg-RX-API-DMAC7.html) |
| EA (1) | EA019935B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2385087T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL189003A0 (cg-RX-API-DMAC7.html) |
| NO (1) | NO20080877L (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007018496A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101335941B1 (ko) | 2005-06-08 | 2013-12-04 | 에스케이바이오팜 주식회사 | 수면-각성 장애의 치료 |
| MX2012000034A (es) | 2009-06-22 | 2012-02-21 | Sk Biopharmaceuticals Co Ltd | Metodos para el tratamiento o la prevencion de la fatiga. |
| US8232315B2 (en) * | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| AU2010316172B2 (en) | 2009-11-06 | 2015-11-12 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| EP2496228B1 (en) | 2009-11-06 | 2014-01-15 | SK Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| RU2019114940A (ru) | 2013-03-13 | 2019-06-28 | ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи | Лечение катаплексии |
| US9226910B2 (en) | 2013-07-18 | 2016-01-05 | Jazz Pharmaceuticals International Iii Limited | Treatment for obesity |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| BR112019025286A2 (pt) | 2017-06-02 | 2020-06-23 | Jazz Pharmaceuticals Ireland Limited | Métodos e composições para tratamento de sonolência excessiva |
| CN114096314A (zh) | 2019-06-27 | 2022-02-25 | 沼泽敏彦 | 痴呆症的治疗和预防药 |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) * | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| KR100858232B1 (ko) * | 2001-02-27 | 2008-09-12 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 카바메이트 화합물을 포함하는 거동 장애 예방 또는 치료용 약제학적 조성물 |
| IL157589A0 (en) * | 2001-02-27 | 2004-03-28 | Ortho Mcneil Pharm Inc | Carbamate compounds for use in preventing or treating bipolar disorder |
| PL365021A1 (en) * | 2001-02-27 | 2004-12-27 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating psychotic disorders |
| PT1383489E (pt) * | 2001-02-27 | 2007-06-21 | Ortho Mcneil Pharm Inc | Compostos carbamato para utilização na prevenção ou tratamento de distúrbios neurodegenerativos |
| US20070021500A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods for neuroprotection |
-
2005
- 2005-07-26 EP EP05775692A patent/EP1928451B1/en not_active Expired - Lifetime
- 2005-07-26 WO PCT/US2005/026439 patent/WO2007018496A1/en not_active Ceased
- 2005-07-26 AT AT05775692T patent/ATE538784T1/de active
- 2005-07-26 JP JP2008523847A patent/JP5094720B2/ja not_active Expired - Fee Related
- 2005-07-26 AU AU2005335241A patent/AU2005335241B9/en not_active Ceased
- 2005-07-26 CA CA2616721A patent/CA2616721C/en not_active Expired - Lifetime
- 2005-07-26 EA EA200800422A patent/EA019935B1/ru not_active IP Right Cessation
- 2005-07-26 ES ES05775692T patent/ES2385087T3/es not_active Expired - Lifetime
- 2005-07-26 KR KR1020087004533A patent/KR101199499B1/ko not_active Expired - Lifetime
- 2005-07-26 CN CN200580051664XA patent/CN101272776B/zh not_active Expired - Fee Related
- 2005-07-26 BR BRPI0520451-8A patent/BRPI0520451A2/pt not_active Application Discontinuation
-
2008
- 2008-01-24 IL IL189003A patent/IL189003A0/en unknown
- 2008-02-19 NO NO20080877A patent/NO20080877L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005335241B2 (en) | 2012-11-15 |
| ATE538784T1 (de) | 2012-01-15 |
| EP1928451B1 (en) | 2011-12-28 |
| CA2616721C (en) | 2014-01-21 |
| EA200800422A1 (ru) | 2008-10-30 |
| JP2009502914A (ja) | 2009-01-29 |
| ES2385087T3 (es) | 2012-07-18 |
| WO2007018496A1 (en) | 2007-02-15 |
| CN101272776A (zh) | 2008-09-24 |
| EA019935B1 (ru) | 2014-07-30 |
| JP5094720B2 (ja) | 2012-12-12 |
| CA2616721A1 (en) | 2007-02-15 |
| KR101199499B1 (ko) | 2012-11-09 |
| KR20080037055A (ko) | 2008-04-29 |
| NO20080877L (no) | 2008-02-19 |
| CN101272776B (zh) | 2012-10-03 |
| AU2005335241A1 (en) | 2007-02-15 |
| AU2005335241B9 (en) | 2012-12-20 |
| EP1928451A1 (en) | 2008-06-11 |
| IL189003A0 (en) | 2008-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20080877L (no) | Fremgangsmater for behandling av substansrelaterte forstyrrelser | |
| NO20071921L (no) | Fremgangsmater for behandling av epileptogenese og epilepsi | |
| YU67703A (sh) | Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja | |
| MY138156A (en) | Carbamate compounds for use in preventing or treating neurodegenerative disorders | |
| WO2007008562A3 (en) | Carbamate compounds for use in treating neurodegenerative disorders | |
| PT1408953E (pt) | Compostos carbamato para utilizacao na prevencao ou tratamento do disturbio bipolar | |
| DE60223506D1 (de) | Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen | |
| BR0207673A (pt) | Compostos de carbamato para o uso no tratamento de dor | |
| PT1399144E (pt) | Compostos carbamato para utilizacao na prevencao ou tratamento de disturbios de ansiedade | |
| TW200744575A (en) | Methods of treating epileptogenesis | |
| WO2008060787A3 (en) | Methods for treatment of cochlear and vestibular disorders | |
| MY149385A (en) | Methods for treating substance-related disorders | |
| DK1408954T3 (da) | Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af neuropatisk smerte | |
| MY136733A (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
| TW200701978A (en) | Methods of treating epileptogenesis and epilepsy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: JOHNSON AND JOHNSON (US) Free format text: TRANSFERIDO DE: JANSSEN PHARMACEUTICA N.V. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |